People Science, a Los Angeles, CA-based direct-to-consumer scientific research company providing a scaled research and development (R&D) platform for alternative medicines, raised $5.3M in Second Seed funding.
The round, which brought total seed funding to $8.5M, was led by Acre Venture Partners with participation from Bluestein Ventures, THIA Ventures and FORM Life Ventures. Lucas Mann, Co-Founder and Managing Partner at Acre Venture Partners, will join the People Science Board of Directors.
The company intends to use the funds to develop the CHLOE technology platform to support additional consumer-facing features as well as to support their growing client pipeline for CHLOE software licensing. The core team will expand to support customer growth and retention.
Led by co-CEOs Belinda Tan and Noah Craft, People Science is building a new clinical research infrastructure for alternative medicines that connects people, doctors, and scientists through its technology platform, CHLOE (the Consumer Health Learning and Organizing Ecosystem). CHLOE is a modular software technology that combines a consumer-facing mobile app with a high-quality clinical research platform. Consumers can use CHLOE to help understand which alternative medicines work best for themselves. Companies and other researchers engage with People Science to test their ideas and products directly or by licensing CHLOE. Sponsored clinical studies with CHLOE began in late 2022, with the goal of launching the app to the public in early 2023.
